Precision Health Clinical Trials

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Conditions:   Breast Cancer;   Lung Cancer;   Gastrointestinal Cancer;   Genitourinary Cancer;   Gynecologic Cancer;   Sarcoma;   Unknown Primary Tumors;   Head and Neck Cancer;   Skin Cancer
Intervention:   Drug: Atezolizumab
Sponsors:   British Columbia Cancer Agency;   Hoffmann-La Roche
Recruiting

For more information, visit the Study URL.

Tessa Jowell BRAIN MATRIX - Platform Study

Condition:   Glioma
Interventions:   Other: Matched Tumour and Blood Sample - Research Pathway;   Other: Matched Tumour and Blood Sample - NHS GMS pathway
Sponsors:   University of Birmingham;   The Brain Tumour Charity;   University of Oxford;   University of Edinburgh;   Genomics England
Recruiting

For more information, visit the Study URL.

Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)

Conditions:   Aspirin Exacerbated Respiratory Disease;   Aspirin-Sensitive Asthma;   Nasal Polyps
Intervention:  
Sponsors:   National Jewish Health;   The Scripps Research Institute
Recruiting

For more information, visit the Study URL.

An Integrative Genomic Approach to Solve tHe Puzzle of sevERe earLy-Onset COPD

Conditions:   COPD;   Chronic Obstructive Pulmonary Disease;   Severe Early-Onset COPD;   SEO-COPD
Intervention:  
Sponsor:   University Medical Center Groningen
Recruiting

For more information, visit the Study URL.

IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient(dMMR)/Microsatellite Instability High (MSI-H)Locally-advanced or Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Biological: IBI310 (anti-CTLA-4 antibody);   Biological: Sintilimab(anti-PD-1 antibody)
Sponsor:   Innovent Biologics (Suzhou) Co. Ltd.
Recruiting

For more information, visit the Study URL.

DOvEEgene Fleur: New Uterine Sampling Tool

Condition:   Women With Suspected or Confirmed Gynecological Disease
Intervention:   Device: DOvEEgene Fleur Sampling
Sponsors:   McGill University;   McGill University Health Centre/Research Institute of the McGill University Health Centre;   GSE Biomedical
Recruiting

For more information, visit the Study URL.

CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma

Condition:   Ovarian Adenocarcinoma
Intervention:   Other: CINSARC signature
Sponsor:   Institut Claudius Regaud
Recruiting

For more information, visit the Study URL.

Immune Resistance Interrogation Study

Conditions:   Cancer;   Solid Tumor;   Metastatic Cancer;   Immune Resistance
Intervention:  
Sponsor:   University Health Network, Toronto
Recruiting

For more information, visit the Study URL.

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Conditions:   Colon Adenocarcinoma;   Stage IIA Colon Cancer AJCC v8
Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Patient Observation
Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
Recruiting

For more information, visit the Study URL.

Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System

Condition:   Adverse Drug Reaction (ADR)
Intervention:  
Sponsors:   University of British Columbia;   Genome British Columbia;   Genome Canada;   Dynacare Laboratories, Inc.
Recruiting

For more information, visit the Study URL.

Pages